NEW YORK, Jan. 23, 2022 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Medallion Financial Corp. (“Medallion” or the “Company”) (NASDAQ: MFIN). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. 7980.
The investigation concerns whether Medallion and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On December 29, 2021, the U.S. Securities and Exchange Commission (“SEC”) filed a complaint alleging that Medallion and certain of its corporate officers had engaged in an unlawful scheme in an effort to reverse the Company’s declining stock price. The charges in the SEC complaint include violations of antifraud, books and records, internal controls, and anti-touting provisions of the federal securities laws.
On this news, Medallion’s stock price fell $1.78 per share, or 21.07%, to close at $6.67 per share on December 29, 2021.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
Robert S. Willoughby
888-476-6529 ext. 7980
- Cytokinetics Announces Data From REDWOOD-HCM OLE andGALACTIC-HF Presented as Late Breaking Science Presentationsat the European Society of Cardiology Heart Failure 2022 Congress - May 23, 2022
- Genius Brands International Announces its Chairman & CEO Andy Heyward will be Appearing Today on Cheddar - May 23, 2022
- Breast Cancer Diagnostics Market is Estimated to Rise at a CAGR of 7% during the Forecast Period, notes TMR Study - May 23, 2022